Benefits and costs of recombinant human erythropoietin for end-stage renal failure: A review benefits and costs of erythropoietin

Paul McNamee, Eddy van Doorslaer, Rob Segaar

Research output: Contribution to journalArticleAcademicpeer-review

13 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Benefits and costs of recombinant human erythropoietin for end-stage renal failure: A review benefits and costs of erythropoietin'. Together they form a unique fingerprint.

Social Sciences

Medicine and Dentistry

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science

Economics, Econometrics and Finance